CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to develop innovative therapies for triple-negative breast cancer by targeting fibroblast activation protein with novel small-molecule inhibitors. It aims to create drug delivery systems that combine chemotherapy and radionuclide therapy for improved treatment efficacy.
Triple-negative breast cancer (TNBC) remains one of the most aggressive subtypes of breast cancer, with limited therapeutic options and a poor prognosis.
To offer dearly needed new treatment perspectives, we want to target fibroblast activation protein (FAP), a protease that is highly expressed on cancer-associated fibroblasts (CAFs) in tumors but negligible in most healthy tissue.
Building on this rationale, the host institution has pioneered novel ketoFAPIs, small-molecule FAP inhibitors with…
UNIVERSITEIT ANTWERPEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
